Cargando…

A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer

The aim of this study was to evaluate the efficacy and tolerability of gefitinib (‘IRESSA’) in Japanese patients with previously untreated stage IV non-small-cell lung cancer (NSCLC). This was a multi-institutional phase II study. Thirty-four patients with previously untreated stage IV NSCLC were en...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suzuki, R, Hasegawa, Y, Baba, K, Saka, H, Saito, H, Taniguchi, H, Yamamoto, M, Matsumoto, S, Kato, K, Oishi, T, Imaizumi, K, Shimokata, K
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2006
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361326/ https://www.ncbi.nlm.nih.gov/pubmed/16670714 http://dx.doi.org/10.1038/sj.bjc.6603159

Ejemplares similares

Prognostic Factors for Short‐term Survival in Patients with Stage IV Non‐small Cell Lung Cancer
por: Ando, Masahiko, et al.
Publicado: (1999)

Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3β/snail signalling pathway
por: Maseki, S, et al.
Publicado: (2012)

Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019)

Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing.
por: Ando, Y., et al.
Publicado: (1997)

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer
por: Yin, Yong-Mei, et al.
Publicado: (2010)

Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib
por: Andersson, Mattias K, et al.
Publicado: (2008)

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer
por: Horiike, A, et al.
Publicado: (2011)

Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer
por: Wong, Matthew K., et al.
Publicado: (2009)

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
por: Douillard, J-Y, et al.
Publicado: (2014)

GENETIC POLYMORPHISMS OF THE ADENOSINE TRIPHOSPHATE-BINDING CASSETTE TRANSPORTERS(ABCG2, ABCB1) AND GEFITINIB TOXICITY
por: TAMURA, MARIKO, et al.
Publicado: (2012)

Gefitinib (‘Iressa’, ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2
por: Nutt, J E, et al.
Publicado: (2004)

Nonspecific crossreacting antigen (NCA) is a major member of the carcinoembryonic antigen (CEA)-related gene family expressed in lung cancer.
por: Hasegawa, T., et al.
Publicado: (1993)

Establishment and characterisation of human carcinoembryonic antigen transgenic mice.
por: Hasegawa, T., et al.
Publicado: (1991)

Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line
por: Yan, Dong, et al.
Publicado: (2015)

Unusual computed tomography findings of radionecrosis after chemoradiation of stage IV hypopharyngeal cancer: a case report
por: Baba, Yuh, et al.
Publicado: (2011)

Prognostic and predictive values of tumour budding in stage IV colorectal cancer
por: Nagata, K., et al.
Publicado: (2020)

Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment
por: Yang, Chih-Jen, et al.
Publicado: (2016)

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
por: Asahina, H, et al.
Publicado: (2006)

M2 macrophages reduce the effect of gefitinib by activating AKT/mTOR in gefitinib‐resistant cell lines HCC827/GR
por: Xiao, Fengqi, et al.
Publicado: (2020)

Effect of Gene Transfer of Tumor Necrosis Factor Receptors into Human Lung Carcinoma Cell Line
por: Ohara, Hisao, et al.
Publicado: (1998)

Polarized electron source development in Japan
por: Nakanishi, T, et al.
Publicado: (1996)

Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients
por: Lim, S-T, et al.
Publicado: (2005)

Selective inhibition of TNF-α-induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib
por: Ueno, Y, et al.
Publicado: (2005)

Association between gefitinib and hemorrhagic cystitis and severely contracted bladder: a case report
por: Arakawa, Maki, et al.
Publicado: (2010)

Development of 700 pps High-Duty-Cycle Line-Type Pulse Modulator
por: Baba, H, et al.
Publicado: (1996)

EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib
por: Kimura, H, et al.
Publicado: (2006)

Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer
por: Ando, M, et al.
Publicado: (2001)

hEGR1 is induced by EGF, inhibited by gefitinib in bladder cell lines and related to EGF receptor levels in bladder tumours
por: Nutt, J E, et al.
Publicado: (2007)

Differences in Home Health Nursing Care for Patients with Parkinson's Disease by Stage of Progress: Patients in Hoehn and Yahr Stages III, IV, and V
por: Iwasa, Yumi, et al.
Publicado: (2021)

Cross-Resistance of Acquired Radioresistant Colorectal Cancer Cell Line to gefitinib and regorafenib
por: Afshar, Saeid, et al.
Publicado: (2020)

Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)
por: Kimura, H, et al.
Publicado: (2007)

Development of radiation-resistant magnet coils for high-intensity beam lines
por: Tanaka, K H, et al.
Publicado: (1993)

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
por: Bozec, A, et al.
Publicado: (2006)

Extensive experience of disease control with gefitinib and the role of prognostic markers
por: Cortes-Funes, H, et al.
Publicado: (2003)

Docosahexaenoic Acid Serving As Sensitizing Agents And Gefitinib Resistance Revertants In EGFR Targeting Treatment
por: Ding, Xuansheng, et al.
Publicado: (2019)

Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells
por: Okubo, S, et al.
Publicado: (2004)

Efficacy of Gefitinib and Methorexate in Patients With Advanced Stage and Recurrent Head and Neck Cancer
por: Irshad, Razia, et al.
Publicado: (2021)

Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
por: Pan, Chi, et al.
Publicado: (2020)

Induction of insulin-like growth factor 2 expression in a mesenchymal cell line co-cultured with an ameloblast cell line
por: Matsumoto, Asako, et al.
Publicado: (2011)

Is primary tumor location an independent prognostic factor in stage IV colon cancer?
por: Yokoyama, Sachio, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_naop9kdu4kubtm455ge47h1s9q